DEUTERATED ISOXAZOLE DERIVATIVES AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR POTENTIATORS
申请人:AstraZeneca AB
公开号:US20170145002A1
公开(公告)日:2017-05-25
The present application relates to a compound of Formula (I), and to uses thereof, such as for the treatment of a neurological or psychoartic disorder.
本申请涉及一种化合物的公式(I),以及其用途,例如用于治疗神经系统或精神障碍。
[EN] CDK8 INHIBITORS AND USES THEREOF<br/>[FR] INHIBITEURS DE CDK8 ET APPLICATIONS DE CEUX-CI
申请人:NIMBUS IRIS INC
公开号:WO2014194201A2
公开(公告)日:2014-12-04
The present invention provides methods of using compounds of formula I: and compositions thereof for the inhibition of CDK8, and the treatment of CDK8-mediated disorders.
本发明提供了使用式I的化合物及其组合物来抑制CDK8和治疗CDK8介导的疾病的方法。
[EN] FLT3 INHIBITORS AND USES THEREOF<br/>[FR] INHIBITEURS DE FLT3 ET LEURS UTILISATIONS
申请人:NIMBUS IRIS INC
公开号:WO2014194242A3
公开(公告)日:2015-10-29
Bulk nanostructure of the prototypical ‘good’ and ‘poor’ solvate ionic liquids [Li(G4)][TFSI] and [Li(G4)][NO<sub>3</sub>]
作者:Thomas Murphy、Sam K. Callear、Nageshwar Yepuri、Karina Shimizu、Masayoshi Watanabe、José N. Canongia Lopes、Tamim Darwish、Gregory G. Warr、Rob Atkin
DOI:10.1039/c6cp00176a
日期:——
mixture of lithium bis(trifluoromethylsulfonyl)imide (Li[TFSI]) in tetraglyme (G4), denoted [Li(G4)][TFSI], and the poor SIL formed from a 1 : 1 mixture of lithiumnitrate (Li[NO3]) in G4, denoted [Li(G4)][NO3], have been studied. In both SILs there are strong Lewis acid–base interactions between Li+ and ligating O atoms. However, the O atoms coordinated to Li+ depend strongly on the counter anion present